Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer

European Journal of Medical Research

Volumn 11, Issue 1, 2006, Pages 7-12

  Kichler Lakomy, C ^a   Budinsky, A C ^a,c   Wolfram, R ^a   Hellan, M ^a   Wiltschke, C ^a   Brodowicz, T ^a   Viernstein, H ^b   Zielinski, Christoph C ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Antigen presentation; Breast cancer; Dendritic cells; Phenotype costimulatory molecules

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; METHOTREXATE; T6 ANTIGEN; TAMOXIFEN; TETANUS TOXOID;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CELL FUNCTION; CELL MATURATION; CELL STRUCTURE; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INCUBATION TIME; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MONOCYTE; PHENOTYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN PRESENTATION; ANTIGENS, CD; BREAST NEOPLASMS; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HUMANS; MIDDLE AGED; PHENOTYPE; SEVERITY OF ILLNESS INDEX; TETANUS TOXOID;

EID: 32344442861     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, et al. (1996). Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196: 137-151.
2. Banchereau J, Steinman RM (1998). Dendritic cells and the control of immunity. Nature 392: 245-252.
3. Coventry BJ (1999). CD1a positive putative tumour infiltrating dendritic cells in human breast cancer. Anticancer Res 19: 3183-3187.
4. Slavik JM, Hutchcroft JE, Bierer BE (1999). CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res 19: 1-24.
5. Wolfram RM, Budinsky AC, Brodowicz T, Kubista M, Kostler WJ, Kichler-Lakomy C, et al. (2000). Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer. Int J Cancer 88: 239-244.
6. Erik AH, Jonuleit H, Saloga J, Knop J (1997). Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73: 309-316.
7. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji, M (1999). Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 31: 323-331.
8. Thurnher M, Radmayr C, Ramoner R, Ebner S, Bock G, Klocker HR et al. (1996). Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 68: 1-7.
9. Kiertscher SM, Luo J, Dubinett SM, Roth MD (2000). Tumors promote altered maturation and early apoptosis of monocyte- derived dendritic cells. J Immunol 164: 1269-1276
10. Satthaporn S, Eremin O (2001). Dendritic cells (II): Role and therapeutic implications in cancer. J R Coll Surg Edinb 46: 159-167.
11. Satthaporn S, Eremin O (2001). Dendritic cells (I): Biological functions. J R Coll Surg Edinb 46: 9-19.
12. Coventry BJ, Austyn JM, Chryssidis S, Hankins D, Harris A (1997). Identification and isolation of CD1a positive putative tumour infiltrating dendritic cells in human breast cancer. Adv Exp Med Biol 417: 571-577.
13. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, et al. (1999). In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190: 1417-1426.
14. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, et al. (1999). Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309-4317.
15. Coventry BJ, Lee PL, Gibbs D, Hart DN (2002). Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer 86: 546-551.
16. Rosen HR, Stierer M, Wolf HM, Eibl MM (1992). Impaired primary antibody responses after vaccination against hepatitis B in patients with breast cancer. Breast Cancer Res Treat 23: 233-240.
17. Zielinski CC, Stuller I, Dorner F, Potzi P, Muller C, Eibl MM (1986). Impaired primary, but not secondary, immune response in breast cancer patients under adjuvant chemotherapy. Cancer 58: 1648-1652.
18. Budinsky AC, Brodowicz T, Wiltschke C, Czerwenka K, Michl I, Krainer M, Zielinski CC (1997). Decreased expression of ICAM-1 and its induction by tumor necrosis factor on breast-cancer cells in vitro. Int J Cancer 71: 1086-1090.
19. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998). Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
20. + T-helper and a T-killer cell. Nature 393: 474-478.
21. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998). T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
22. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. (2003). Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170: 1257-1266.
23. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, et al. (2003). Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89: 1463-1472.